Stock listing
NASDAQ:VERU Veru Inc. Stock
Home listing (NASDAQ) of Veru Inc.
Follow Veru Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:VERU
$1.94 USD -0.37 (-16.0%)
Close on Nov 20, 2026
- Day range
- $1.93 – $2.17 USDNov 20, 2026
- Volume
- 247,921 sharesNov 20, 2026
- Market cap
- $33.08M USDAt the close on Nov 20, 2026 · price × 17.05M shares outstanding
- 52-week range
- $1.93 – $7.33 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $468,881 USDMedian day 130,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VERU · Home | $1.94 USD | -0.37 (-16.0%) | 247,921 | $2.09 | $2.17 | $1.93 | $2.31 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VERU · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.94 | -0.37 | -16.0% | $2.09 | $2.17 | $1.93 | 247,921 | |
| $2.31 | +0.17 | +7.9% | $2.16 | $2.34 | $2.13 | 467,111 | |
| $2.14 | +0.06 | +2.9% | $2.09 | $2.20 | $2.075 | 305,002 | |
| $2.08 | -0.01 | -0.5% | $2.08 | $2.14 | $2.03 | 198,888 | |
| $2.09 | -0.03 | -1.4% | $2.15 | $2.15 | $2.08 | 90,524 | |
| $2.12 | -0.02 | -0.9% | $2.10 | $2.15 | $2.079 | 91,575 | |
| $2.14 | +0.02 | +0.9% | $2.13 | $2.17 | $2.071 | 38,942 | |
| $2.12 | -0.07 | -3.2% | $2.17 | $2.21 | $2.06 | 128,464 | |
| $2.19 | +0.07 | +3.3% | $2.12 | $2.21 | $2.105 | 134,522 | |
| $2.12 | +0.06 | +2.9% | $2.08 | $2.15 | $2.07 | 137,144 | |
| $2.06 | -0.14 | -6.4% | $2.20 | $2.20 | $2.04 | 214,771 | |
| $2.20 | +0.04 | +1.9% | $2.18 | $2.23 | $2.10 | 180,514 | |
| $2.16 | 0.00 | 0.0% | $2.18 | $2.22 | $2.11 | 103,489 | |
| $2.16 | -0.03 | -1.4% | $2.20 | $2.22 | $2.075 | 249,370 | |
| $2.19 | -0.04 | -1.8% | $2.25 | $2.26 | $2.16 | 78,878 | |
| $2.23 | -0.04 | -1.8% | $2.27 | $2.33 | $2.22 | 56,935 | |
| $2.27 | -0.01 | -0.4% | $2.27 | $2.30 | $2.24 | 73,162 | |
| $2.28 | +0.07 | +3.2% | $2.22 | $2.34 | $2.22 | 157,711 | |
| $2.21 | -0.03 | -1.3% | $2.25 | $2.26 | $2.18 | 86,578 | |
| $2.24 | -0.05 | -2.2% | $2.29 | $2.32 | $2.22 | 122,600 | |
| $2.29 | -0.01 | -0.4% | $2.30 | $2.30 | $2.24 | 85,800 | |
| $2.30 | -0.08 | -3.4% | $2.37 | $2.41 | $2.28 | 99,800 | |
| $2.38 | +0.07 | +3.0% | $2.31 | $2.40 | $2.31 | 89,700 | |
| $2.31 | +0.01 | +0.4% | $2.30 | $2.35 | $2.27 | 88,100 | |
| $2.30 | -0.14 | -5.7% | $2.41 | $2.48 | $2.27 | 305,400 | |
| $2.44 | +0.31 | +14.6% | $2.14 | $2.48 | $2.12 | 505,300 | |
| $2.13 | -0.06 | -2.7% | $2.26 | $2.29 | $2.11 | 275,200 | |
| $2.19 | -0.22 | -9.1% | $2.41 | $2.42 | $2.18 | 169,200 | |
| $2.41 | -0.05 | -2.0% | $2.44 | $2.45 | $2.40 | 85,500 | |
| $2.46 | +0.04 | +1.7% | $2.42 | $2.49 | $2.42 | 128,900 | |
| $2.42 | -0.04 | -1.6% | $2.44 | $2.52 | $2.39 | 147,600 | |
| $2.46 | -0.01 | -0.4% | $2.42 | $2.54 | $2.41 | 202,400 | |
| $2.47 | -0.08 | -3.1% | $2.54 | $2.75 | $2.44 | 1,517,500 | |
| $2.55 | +0.04 | +1.6% | $2.51 | $2.62 | $2.50 | 88,600 | |
| $2.51 | -0.03 | -1.2% | $2.56 | $2.56 | $2.50 | 104,900 | |
| $2.54 | -0.12 | -4.5% | $2.65 | $2.65 | $2.53 | 70,700 | |
| $2.66 | +0.10 | +3.9% | $2.58 | $2.70 | $2.51 | 183,000 | |
| $2.56 | +0.03 | +1.2% | $2.53 | $2.58 | $2.50 | 33,100 | |
| $2.53 | -0.01 | -0.4% | $2.52 | $2.57 | $2.51 | 101,300 | |
| $2.54 | +0.03 | +1.2% | $2.55 | $2.57 | $2.50 | 115,800 | |
| $2.51 | +0.05 | +2.0% | $2.42 | $2.52 | $2.42 | 87,400 | |
| $2.46 | -0.04 | -1.6% | $2.49 | $2.51 | $2.43 | 94,000 | |
| $2.50 | +0.06 | +2.5% | $2.46 | $2.52 | $2.42 | 121,400 | |
| $2.44 | +0.03 | +1.2% | $2.44 | $2.49 | $2.43 | 158,200 | |
| $2.41 | +0.02 | +0.8% | $2.39 | $2.44 | $2.36 | 102,900 | |
| $2.39 | +0.07 | +3.0% | $2.35 | $2.40 | $2.35 | 93,900 | |
| $2.32 | -0.02 | -0.9% | $2.34 | $2.37 | $2.31 | 130,300 | |
| $2.34 | 0.00 | 0.0% | $2.36 | $2.36 | $2.29 | 125,300 | |
| $2.34 | -0.10 | -4.1% | $2.41 | $2.44 | $2.34 | 207,500 | |
| $2.44 | -0.06 | -2.4% | $2.52 | $2.53 | $2.43 | 239,300 | |
| $2.50 | +0.02 | +0.8% | $2.52 | $2.53 | $2.46 | 181,400 | |
| $2.48 | -0.10 | -3.9% | $2.59 | $2.59 | $2.48 | 264,800 | |
| $2.58 | -0.06 | -2.3% | $2.81 | $2.85 | $2.55 | 1,340,500 | |
| $2.64 | -0.01 | -0.4% | $2.65 | $2.73 | $2.63 | 143,500 | |
| $2.65 | -0.10 | -3.6% | $2.75 | $2.77 | $2.65 | 75,400 | |
| $2.75 | +0.06 | +2.2% | $2.70 | $2.76 | $2.65 | 202,600 | |
| $2.69 | -0.11 | -3.9% | $2.80 | $2.82 | $2.69 | 203,200 | |
| $2.80 | +0.17 | +6.5% | $2.63 | $2.83 | $2.59 | 250,000 | |
| $2.63 | -0.11 | -4.0% | $2.71 | $2.73 | $2.61 | 92,700 | |
| $2.74 | -0.06 | -2.1% | $2.82 | $2.84 | $2.71 | 122,500 | |
| $2.80 | +0.09 | +3.3% | $2.73 | $2.82 | $2.70 | 169,400 | |
| $2.71 | +0.12 | +4.6% | $2.60 | $2.79 | $2.60 | 227,020 | |
| $2.59 | -0.05 | -1.9% | $2.64 | $2.64 | $2.50 | 102,569 | |
| $2.64 | +0.06 | +2.3% | $2.56 | $2.68 | $2.56 | 177,500 | |
| $2.58 | -0.06 | -2.3% | $2.65 | $2.68 | $2.52 | 135,400 |
Splits
1 split · NASDAQ:VERU · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:VERU
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function
Latest earnings call · Aug 10, 2026
Veru (NASDAQ:VERU) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 16, 2026
Obesity Week 2026
Conference · 15 slides
Latest news
Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function
Nov 17, 2026
Closed $2.14 (+2.9%) on Nov 17, 2026
Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026
Nov 9, 2026
Closed $2.19 (+3.3%) on Nov 9, 2026
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
Sep 8, 2026
Closed $2.58 (-2.3%) on Sep 8, 2026
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
Sep 2, 2026
Closed $2.75 (+2.2%) on Sep 2, 2026
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Aug 10, 2026
Closed $2.77 (+18.9%) on Aug 10, 2026
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
Aug 4, 2026
Closed $2.37 (+4.9%) on Aug 4, 2026
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
Aug 3, 2026
Closed $2.26 (+0.9%) on Aug 3, 2026
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
Jul 30, 2026
Closed $2.22 (+0.5%) on Jul 30, 2026
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Jul 27, 2026
Closed $2.28 (+1.3%) on Jul 27, 2026
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
Jul 7, 2026
Closed $2.88 (+1.8%) on Jul 7, 2026
Veru Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 150 in all · newest Nov 17, 2026 · oldest 2019
- Calls
- 19 calls with a replay · 19 with a transcript · latest Aug 10, 2026
- Decks
- 40 decks · latest Nov 16, 2026
Where Veru Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VERU · Home listing · This page | NASDAQ | United States | USD |
| BOATS:VERU | BOATS | United States | USD |
| gettex:FMW0 | gettex | Germany | EUR |
| Frankfurt:FMW0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A41ES4 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A41ES4 | LS Exchange | Germany | EUR |
| Munich:FMW0 | Munich | Germany | EUR |
Valuation
Price/book 1.2× against a median of 1.3×: 5th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $9.20M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.92
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Veru Inc. · NASDAQ:VERU | US$33.08M | US$9.20M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.92 |
| Cue Biopharma, Inc. · NASDAQ:CUE | US$34.69M | −US$23.25M | n/a | −0.7× | n/a | 0.9× | −580.0% | 0.0× | 2.35 |
| B&K Corporation Limited Class H · HKEX:2396 | US$33.15M | −US$47.10M | n/a | −602× | n/a | 0.4× | n/a | 0.0× | n/a |
| Actinium Pharmaceuticals, Inc. (Delaware) · AMEX:ATNM | US$33.01M | US$5.49M | 3.1× | n/a | 0.6× | 1.3× | n/a | 0.1× | 0.71 |
| Neurizon Therapeutics Limited · ASX:NUZ | US$32.76M | US$26.54M | n/a | 2.3× | n/a | 3.9× | −61.0% | 0.3× | n/a |
| CJ Bioscience. Inc. · KRX:311690 | US$32.52M | US$1.91M | n/a | 0.7× | n/a | 1.0× | −607.2% | 0.0× | n/a |
| Transcenta Holding Limited · HKEX:6628 | US$32.41M | US$52.52M | n/a | 12.4× | n/a | 0.4× | −569.5% | 0.3× | n/a |
| Enimmune Corporation · TPEX:6564 | US$31.74M | US$26.87M | n/a | 18.4× | n/a | 10.4× | −341.0% | 0.3× | n/a |
| Molecure SA · GPW:MOC | US$31.66M | US$29.60M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Sareum Holdings plc · LSE:SAR | US$31.03M | US$27.78M | n/a | n/a | n/a | 19.9× | n/a | 0.0× | n/a |
| Isofol Medical AB · OMXSTO:ISOFOL | US$31.03M | US$19.80M | n/a | n/a | n/a | 3.3× | n/a | 0.0× | n/a |
| Median of the others | US$32.46M | US$23.17M | 3.1× | 1.5× | 0.6× | 1.3× | −569.5% | 0.0× | 1.53 |
Forecasts
3 strong buy · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 25.67 USD · Analysts' mean
- EPS, year to Sep 2026
- -0.87 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Mitchell Steiner | Chairman, President, and Chief Executive Officer |
| Michele Greco | Chief Financial Officer and Chief Administrative Officer |
| Philip Greenberg | Executive Vice President, General Counsel |
| Samuel Fisch | Executive Director, Investor Relations & Corporate Communications |
| Domingo Rodriguez | Executive Vice President, Global Clinical Operations |
| Gary Bird | Executive Vice President, Quality and Regulatory Affairs |
| Kevin Gilbert | Executive Vice President, Corporate Development |
| Harry Fisch | |
| K. Gary Barnette | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Mitchell Steiner | Chairman, President, and Chief Executive Officer |
| Grace S. Hyun | Director |
| Harry Fisch | |
| Loren Katzovitz | Director |
| Lucy Lu | Director |
| Michael L. Rankowitz | Director |
| Samuel Fisch | Executive Director, Investor Relations & Corporate Communications |
Events
- Next results
- Dec 16, 2026 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Veru (NASDAQ:VERU) Q3 2026 Earnings Call | Mon, Aug 10, 2026 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q2 2026 Earnings Call | Wed, May 13, 2026 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q1 2026 Earnings Call | Wed, Feb 04, 2026 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q4 2025 Earnings Call | Wed, Dec 17, 2025 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q3 2025 Earnings Call | Tue, Aug 12, 2025 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q2 2025 Earnings Call | Thu, May 08, 2025 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q1 2025 Earnings Call | Thu, Feb 13, 2025 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q3 2024 Earnings Call | Thu, Aug 08, 2024 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q2 2024 Earnings Call | Wed, May 08, 2024 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q1 2024 Earnings Call | Thu, Feb 08, 2024 · 8:00 AM ET | Replay |
All 19 calls
| Call | When | Status |
|---|---|---|
| Veru (NASDAQ:VERU) Q3 2023 Earnings Call | Thu, Aug 10, 2023 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q2 2023 Earnings Call | Thu, May 11, 2023 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q1 2023 Earnings Call | Thu, Feb 09, 2023 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q4 2022 Earnings Call | Mon, Dec 05, 2022 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q3 2022 Earnings Call | Thu, Aug 11, 2022 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q2 2022 Earnings Call | Thu, May 12, 2022 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q1 2022 Earnings Call | Wed, Feb 09, 2022 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q4 2021 Earnings Call | Thu, Dec 02, 2021 · 8:00 AM ET | Replay |
| Veru (NASDAQ:VERU) Q4 2020 Earnings Call | Wed, Dec 09, 2020 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Aug 10, 2026 · Before open | +18.9% |
| Q2 2026 | May 13, 2026 · Before open | −0.4% |
| Q1 2026 | Feb 11, 2026 · Before open | −0.4% |
| Q4 2025 | Dec 1, 2025 | −4.8% |
| Q3 2025 | Aug 12, 2025 · Before open | −11.7% |
| Q2 2025 | May 8, 2025 · Before open | +4.2% |
| Q1 2025 | Feb 13, 2025 · Before open | −4.5% |
| Q4 2024 | Dec 5, 2024 · Before open | −1.4% |
| Q3 2024 | Aug 8, 2024 · Before open | +5.3% |
| Q2 2024 | Apr 1, 2024 · After close | +1.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Feb 14, 2024 · After close | +0.7% |
| Q4 2023 | Dec 8, 2023 · After close | −26.3% |
| Q3 2023 | Aug 10, 2023 · Before open | +0.9% |
| Q2 2023 | May 11, 2023 · Before open | −17.4% |
| Q1 2023 | Feb 9, 2023 · Before open | −22.6% |
| Q4 2022 | Dec 5, 2022 · Before open | +5.8% |
| Q3 2022 | Aug 11, 2022 · Before open | +36.0% |
| Q2 2022 | May 12, 2022 · Before open | +10.7% |
| Q1 2022 | Feb 9, 2022 · Before open | +6.2% |
| Q4 2021 | Dec 2, 2021 · Before open | +0.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Obesity Week 2026 | Conference | 15 slides | Nov 16, 2026 |
| 2026 Cantor Global Healthcare Conference | Conference | 59 slides | September 2026 |
| Q2 2026 Earnings Presentation | Earnings | 8 slides | May 13, 2026 |
| 4th Edition of World Obesity and Weight Management Congress 2024 | Conference | 34 slides | Oct 24, 2024 |
| 2024 Cantor Global Healthcare Conference | Conference | 45 slides | September 2024 |
| Leerink Therapeutics Forum: I&I and Metabolism 2024 | Conference | 33 slides | Jul 9, 2024 |
| Jefferies Global Healthcare Conference 2024 | Conference | 27 slides | Jun 5, 2024 |
| GLP-1 Summit 2024 | Conference | 26 slides | May 16, 2024 |
| Oppenheimer 34th Annual Healthcare Life Sciences Conference 2024 | Conference | 26 slides | Feb 13, 2024 |
| Investor Presentation (December 2023) | Investor deck | 19 slides | Dec 13, 2023 |
All 40 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock (or pre-funded warrants) with accompanying Series A and Series B warrants Closed: US$23.4M raised · US$3 a share · Canaccord Genuity LLC +1 Dealers: Canaccord Genuity LLC (co-lead), Oppenheimer & Co. Inc. (co-lead) Use of proceeds: To start the Phase 2b PLATEAU clinical trial of enobosarm | Dec 17, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.9M | 16.3M | 39.4M | 61.3M | 42.6M | 31.8M | 15.9M | 13.7M | 22.1M | |
| Cost of revenue | 11.0M | 8.73M | 8.76M | 13.3M | 11.8M | 10.1M | 7.09M | 6.64M | 8.78M | |
| Gross profit | 5.85M | 7.57M | 30.6M | 47.9M | 30.8M | 21.7M | 8.77M | 7.02M | 13.3M | |
| Research and development | 15.6M | 12.8M | 51.2M | 70.9M | 32.7M | 16.9M | 13.7M | 10.9M | 3.08M | 99.4K |
| Selling, general and administrative | 31.2M | 48.1M | 43.2M | 20.7M | 14.5M | 14.3M | 14.8M | 11.5M | 8.66M | |
| Operating income | -24.8M | -36.2M | -93.8M | -83.5M | 13.0M | -14.7M | -6.44M | -20.9M | -8.49M | 3.02M |
| Depreciation and amortization | 152.1K | 268.2K | 269.9K | 138.0K | 98.0K | 146.0K | 176.8K | 334.0K | 422.9K | |
| EBITDA | -24.6M | -35.9M | -93.5M | -83.4M | 13.1M | -14.6M | -20.7M | -8.16M | 3.44M | |
| Interest expense | 607.5K | 2.43M | 4.37M | 4.89M | 4.62M | 4.71M | 2.95M | |||
| Income before tax | -92.7M | -83.8M | 4.27M | -20.1M | -12.3M | -23.1M | -8.60M | 2.81M | ||
| Income tax | 0 | 0 | 480.2K | 236.4K | -3.13M | -1.08M | -303.9K | 866.1K | -1.99M | 2.47M |
| Net income | -22.7M | -37.8M | -93.2M | -84.0M | 7.39M | -19.0M | -12.0M | -23.9M | -6.61M | 344.7K |
| Earnings per share, basic | -1.55 | -2.80 | -1.10 | -1.05 | 0.10 | -0.28 | -0.19 | -0.44 | -0.25 | 0.01 |
| Earnings per share, diluted | -1.10 | -1.05 | 0.09 | -0.28 | -0.19 | -0.44 | -0.25 | 0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 15.8M | 24.9M | 9.63M | 3.76M | 3.28M | 2.39M | ||||
| Receivables | 3.96M | 4.51M | 3.55M | 8.79M | 5.23M | 5.02M | 3.97M | 3.42M | 10.8M | |
| Inventory | 4.14M | 6.70M | 8.62M | 5.57M | 6.70M | 3.65M | 2.30M | 2.77M | 2.49M | |
| Current assets | 18.9M | 35.2M | 22.9M | 104.0M | 151.8M | 27.0M | 16.8M | 11.2M | 10.3M | 16.3M |
| Property, plant and equipment | 364.8K | 481.4K | 1.65M | 1.19M | 592.6K | 312.7K | 351.9K | 404.6K | 555.5K | 825.1K |
| Goodwill | 6.88M | 6.88M | 6.88M | 6.88M | 6.88M | 6.88M | 6.88M | 6.88M | 6.88M | |
| Total assets | 29.8M | 60.4M | 50.0M | 135.4M | 178.1M | 51.5M | 53.6M | 48.5M | 55.3M | 38.6M |
| Accounts payable | 3.12M | 2.26M | 12.9M | 22.0M | 3.41M | 2.81M | 3.12M | 3.23M | 2.69M | 701.0K |
| Current liabilities | 7.79M | 11.9M | 17.8M | 38.7M | 15.8M | 14.7M | 14.0M | 13.6M | 5.49M | 3.35M |
| Long-term debt | 1.75M | |||||||||
| Total debt | 1.75M | |||||||||
| Total liabilities | 11.5M | 28.1M | 30.3M | 52.6M | 25.9M | 21.4M | 21.3M | 19.0M | 6.88M | 4.69M |
| Shareholders' equity | 18.3M | 32.3M | 19.7M | 82.8M | 154.5M | 30.1M | 32.3M | 29.5M | 48.5M | 33.9M |
| Shares outstanding | 14.7M | 14.6M | 91.8M | 80.5M | 80.0M | 69.9M | 65.0M | 55.3M | 53.2M | 29.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -30.0M | -21.7M | -88.0M | -47.5M | -15.6M | -1.93M | -5.49M | -11.5M | 982.9K | -1.71M |
| Capital spending | -1.08K | -158.3K | -665.7K | -733.1K | -376.6K | -105.8K | -108.5K | -50.7K | -133.5K | -6.37K |
| Free cash flow | -30.0M | -21.8M | -88.7M | -48.2M | -15.9M | -2.04M | -5.59M | -11.6M | 849.4K | -1.72M |
| Cash from investing | 25.1M | 146.2K | 6.33M | 4.27M | 14.6M | -105.8K | -108.5K | -50.7K | -90.4K | -6.37K |
| Cash from financing | -4.22M | 36.8M | 11.1M | 1.07M | 109.7M | 9.33M | 8.13M | 12.1M | ||
| Change in cash | -9.12M | 15.3M | -70.6M | -42.2M | 108.8M | 7.29M | 2.54M | 481.9K | 892.5K | -1.72M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 8-K · Current report | Jul 2, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jul 2, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 4, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | May 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 16, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 16, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 13, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 13, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 13, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 13, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 7, 2026 | Offer document | SEC |
| S-3 · Registration statement | Apr 7, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 13, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 11, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Jan 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 28, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Dec 17, 2025 | Offer document | SEC |
| 10-K · Annual report | Dec 17, 2025 | Annual report | SEC |
| 8-K · Current report | Dec 17, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 30, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Oct 29, 2025 | Offer document | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2025 | Current report | SEC |
| 8-K · Current report | Aug 27, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Current report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 8-K · Current report | Jul 25, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Jul 15, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jun 10, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 10, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 9, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 14, 2025 | Management or board change | SEC |
| 8-K · Current report | Feb 28, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Jan 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jan 3, 2025 | Acquisition or disposal | SEC |
| EFFECT · Notice that a registration is effective | Dec 17, 2024 | Other filings | SEC |
| 10-K · Annual report | Dec 16, 2024 | Annual report | SEC |
| POS AM · Amendment to an effective registration | Dec 12, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 20, 2024 | Material contract | SEC |
| 8-K · Current report | Aug 30, 2024 | Current report | SEC |
| 8-K · Current report | Aug 23, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 2, 2024 | Management or board change | SEC |
| 8-K · Current report | Jul 2, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 21, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 20, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jun 18, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 8-K · Current report | May 22, 2024 | Current report | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 9, 2024 | Meeting notice | SEC |
| DEFR14A | May 9, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 8-K · Current report | Apr 26, 2024 | Material contract | SEC |
| 8-K · Current report | Apr 25, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Apr 24, 2024 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Apr 1, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 1, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 22, 2024 | Meeting notice | SEC |
| 8-K · Current report | Feb 27, 2024 | Current report | SEC |
| NT 10-Q · Late filing notice | Feb 15, 2024 | Explanation request | SEC |
| 8-K · Current report | Feb 15, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 8, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 26, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Jan 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 26, 2024 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Dec 26, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Dec 18, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Dec 15, 2023 | Offer document | SEC |
| 424B5 · Prospectus | Dec 13, 2023 | Offer document | SEC |
| 424B5 · Prospectus | Dec 13, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 13, 2023 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 8, 2023 | Big-stake notice | SEC |
| 10-K · Annual report | Dec 8, 2023 | Annual report | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 10-Q/A · Quarterly report, amended | Nov 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 15, 2023 | Current report | SEC |
| 8-K · Current report | Oct 2, 2023 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Sep 28, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Sep 11, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 8-K · Current report | Jul 28, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 12, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 12, 2023 | Meeting notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 8, 2023 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | May 25, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 22, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 19, 2023 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | May 15, 2023 | Meeting notice | SEC |
| S-3 · Registration statement | May 12, 2023 | Offer document | SEC |
| 8-K · Current report | May 12, 2023 | Material contract | SEC |
| 424B5 · Prospectus | May 12, 2023 | Offer document | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| 8-K · Current report | May 3, 2023 | Material contract | SEC |
| 424B5 · Prospectus | May 3, 2023 | Offer document | SEC |
| 8-K · Current report | Apr 20, 2023 | Acquisition or disposal | SEC |
| SC 13G · Big-stake notice | Apr 19, 2023 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 17, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 13, 2023 | Other filings | SEC |
| 8-K · Current report | Apr 13, 2023 | Material contract | SEC |
| 8-K · Current report | Apr 12, 2023 | Current report | SEC |
| S-3/A · Registration statement, amended | Apr 11, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 31, 2023 | Other filings | SEC |
| 8-K · Current report | Mar 31, 2023 | Meeting outcome | SEC |
| UPLOAD · Letter from the SEC | Mar 27, 2023 | Other filings | SEC |
| S-3 · Registration statement | Mar 16, 2023 | Offer document | SEC |
| 8-K · Current report | Mar 14, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 10, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Feb 9, 2023 | Results | SEC |
| DEFA14A · Additional proxy material | Jan 27, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 27, 2023 | Meeting notice | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Veru Inc.’s releases · as of Aug 6, 2026
- Common shares
- 17,050,320
- Fully diluted
- 17,050,320
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 17,050,320 | Aug 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Aug 6, 2026 | 17,050,320 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lucy Lu Other companies: Fortress Biotech, Inc. (Director · Dec 14, 2022 – Jan 1, 2025 · Past) | Director · Since at least Nov 2, 2022 |
| Michael L. Rankowitz Other companies: Carlyle Secured Lending, Inc. (Director · Apr 12, 2013 – Apr 12, 2013 · Past) | Director · Since at least Mar 20, 2018 |
| Domingo Rodriguez | Executive Vice President, Global Clinical Operations · Since at least Nov 5, 2026 |
| Donna Felch | Director · Feb 2, 2006 – Oct 31, 2016 · Past |
| Gary Bird | Executive Vice President, Quality and Regulatory Affairs · Since at least Nov 5, 2026 |
| Grace S. Hyun | Director · Since at least Aug 11, 2020 |
| Harry Fisch | Chief Corporate Officer, Director · Since at least Apr 22, 2022 |
| Harry Fisch | Director · Since at least Nov 4, 2026 |
| Karen Louise King | President and CEO, Director · Jan 20, 2014 – Feb 5, 2015 · Past |
| Kevin Gilbert | Executive Vice President, Corporate Development · Since at least Nov 5, 2026 |
All 20 people
| Person | Seat |
|---|---|
| K. Gary Barnette | Chief Scientific Officer · Since at least Jan 27, 2025 |
| Loren M. Katzovitz | Director · Since at least Aug 1, 2024 |
| Michele Greco | Chief Financial Officer and Chief Administrative Officer · Since at least Sep 30, 2015 |
| Mitchell S. Steiner | Chairman, President, and Chief Executive Officer · Since at least Sep 8, 2026 |
| Philip Greenberg | Executive Vice President, General Counsel · Since at least Nov 5, 2026 |
| Richard E Wenninger | Director · Dec 8, 2011 – Dec 9, 2014 · Past |
| Robert Getzenberg | Chief Scientific Officer · Mar 20, 2018 – May 2, 2018 · Past |
| Samuel Fisch | Executive Director, Investor Relations & Corporate Communications · Since at least Sep 8, 2026 |
| Stephen M Dearholt | Director · Jan 4, 2012 – Jan 16, 2015 · Past |
| William R Gargiulo Jr | Director · May 23, 2016 – May 23, 2016 · Past |
Log in to ask 6ix AI your own questions about Veru Inc.